Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/bcp.12814 http://scihub22266oqcxt.onion/10.1111/bcp.12814 C4767196!4767196!26505271     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26505271&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Br+J+Clin+Pharmacol 2016 ; 81 (3): 488-95 Nephropedia Template TP {{tp|p=26505271|t=2016. Pharmacological treatment of cardiac glycoside poisoning |pdf=|usr=}}{{26505271}} gab.com Text Pharmacological treatment of cardiac glycoside poisoning JO: Br J Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=26505271 #FOAvip Cardiac glycosides are an important cause of poisoning, reflecting their widespread clinical usage and presence in natural sources. Poisoning can manifest as varying degrees of toxicity. Predominant clinical features include gastrointestinal signs, bradycardia and heart block. Death occurs from ventricular fibrillation or tachycardia. A wide range of treatments have been used, the more common including activated charcoal, atropine, ??adrenoceptor agonists, temporary pacing, anti?digoxin Fab and magnesium, and more novel agents include fructose?1,6?diphosphate (clinical trial in progress) and anticalin. However, even in the case of those treatments that have been in use for decades, there is debate regarding their efficacy, the indications and dosage that optimizes outcomes. This contributes to variability in use across the world. Another factor influencing usage is access. Barriers to access include the requirement for transfer to a specialized centre (for example, to receive temporary pacing) or financial resources (for example, anti?digoxin Fab in resource poor countries). Recent data suggest that existing methods for calculating the dose of anti?digoxin Fab in digoxin poisoning overstate the dose required, and that its efficacy may be minimal in patients with chronic digoxin poisoning. Cheaper and effective medicines are required, in particular for the treatment of yellow oleander poisoning which is problematic in resource poor countries. Twit Text FOAVip Pharmacological treatment of cardiac glycoside poisoning ????Br J Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=26505271 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26505271 #FOAvip English Wikipedia <ref>{{Cite pmid|26505271}}</ref> Pharmacological treatment of cardiac glycoside poisoning #MMPMID26505271 Roberts DM; Gallapatthy G; Dunuwille A; Chan BS Br J Clin Pharmacol 2016[Mar]; 81 (3): 488-95 PMID26505271show ga Cardiac glycosides are an important cause of poisoning, reflecting their widespread clinical usage and presence in natural sources. Poisoning can manifest as varying degrees of toxicity. Predominant clinical features include gastrointestinal signs, bradycardia and heart block. Death occurs from ventricular fibrillation or tachycardia. A wide range of treatments have been used, the more common including activated charcoal, atropine, ??adrenoceptor agonists, temporary pacing, anti?digoxin Fab and magnesium, and more novel agents include fructose?1,6?diphosphate (clinical trial in progress) and anticalin. However, even in the case of those treatments that have been in use for decades, there is debate regarding their efficacy, the indications and dosage that optimizes outcomes. This contributes to variability in use across the world. Another factor influencing usage is access. Barriers to access include the requirement for transfer to a specialized centre (for example, to receive temporary pacing) or financial resources (for example, anti?digoxin Fab in resource poor countries). Recent data suggest that existing methods for calculating the dose of anti?digoxin Fab in digoxin poisoning overstate the dose required, and that its efficacy may be minimal in patients with chronic digoxin poisoning. Cheaper and effective medicines are required, in particular for the treatment of yellow oleander poisoning which is problematic in resource poor countries. äPharmacological treatment of cardiac glycoside poisoning (epmc).pdf DeepDyve Pubget Overpricing